Work

A Case of Good Efficacy of Tolvaptan in a Patient with Markedly Enlarged Polycystic Kidney

Year: 2024

Type: article

Abstract: A 61-year-old patient with autosomal dominant polycystic kidney disease (Irazabal class 1E) in whom renal function had decreased and kidney size had increased over the past 3 years (change in serum creatinine, 1.3 mg/dL to 1.5 mg/dL; change in total kidney volume, 5632 cm3 to 7301 cm3) was treated with tolvaptan 60 mg/day. After 8 years of tolvaptan treatment, serum creatinine remained at 1.51 mg/dL, and total kidney volume was at 6812 cm3. Adequate salt intake and good weight control may have resulted in good outcomes, even in patients with treatment-resistant giant cystic kidney disease.

Source: Journal of Clinical Nephrology

DOI: 10.29328/journal.jcn.1001135

Authors: Masato Mizuta, Tatsuya Suwabe, Akinari Sekine, Masayuki Yamanouchi, Hiroki Mizuno, Daisuke Ikuma, Eiko Hasegawa, Yuki Oba, Noriko Inoue, Makoto Fukuda, Motoaki Miyazono, Takehiko Wada, Naoki Sawa, Yoshifumi Ubara

Institutions: Saga University, Toranomon Hospital Kajigaya, Okinaka Memorial Institute for Medical Research

Language: English

Topic: Genetic and Kidney Cyst Diseases

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4401869005

FWCI:

Cites: 10

Cited by:

Related to: 10